相关实验视频

Updated: Sep 9, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

一种工程化学ACE2-HR2对SARS-CoV-2变种表现出强大且广泛的活性

Wenwen Bi¹, Tao Zhu¹, Yawen Xu¹

¹Laboratory of Advanced Biotechnology, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou, 311215, China.

Antiviral research

|August 30, 2025

概括

一种新的,A3M6L35HR2 (FL),显示出强大的潜力作为一种针对SARS-CoV-2变种的广泛抗病毒药物. 这种工程有效地抑制病毒的进入和膜融合, 提供了一个有前途的治疗选择.

科学领域:

病毒学
药物发现
生物化学

背景情况:

由于疫苗在预防传播方面的局限性,持续的SARS-CoV-2循环需要广泛的抗病毒药物.
目前的治疗策略面临着新出现的SARS-CoV-2变种的挑战.

研究的目的:

设计一种新的无胆固醇重组,A3M6L35HR2 (FL),对抗SARS-CoV-2具有增强的抗病毒活性.
评估A3M6L35HR2 (FL) 对各种病毒变异的抑制作用和作用机制.

主要方法:

通过优化来自A1L35HR2的6个突变的A3M2仿真开发了A3M6L35HR2 (FL).
对包括Omicron亚系在内的各种SARS-CoV-2变种进行了抑制功效评估 (IC50).
测量了对病毒HR1域的α-螺旋和结合亲和力 (KD),以了解作用机制.

主要成果:

A3M6L35HR2 (FL) 对SARS-CoV-2变种表现出优异的抑制功效 (IC50: 1.716.2 nM),比A1L35HR2有2至29倍的改善.
该具有较高的α-性 (70%) 和较强的结合亲和力 (KD = 0. 03 nM) 对HR1域.
在纳米度下有效抑制了A3M6L35HR2 (FL) 的尖端介导膜融合.

结论:

A3M6L35HR2 (FL) 是一种高效的抗病毒,对各种SARS-CoV-2变种有效.
增强的α-螺旋性和结合亲和力有助于其强大的病毒进入抑制.
A3M6L35HR2 (FL) 是对当前和未来的SARS-CoV-2菌株进行治疗的有希望的候选物.

关键词:

在ACE2中广泛的抗病毒药物 HR2 其他类冠状病毒

更多相关视频

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

相关概念视频

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...